List of Contract Research Companies in United Kingdom - 36

We are lateral flow CDMO experts based in the UK supporting global customers bring their assays to market, from proof of concept, through optimisation and scale up to routine manufacture, along with full-service regulatory consultancy support. Get in touch: email info@abingdonhealth.com today. We believe that by developing the high quality, effective lateral flow rapid tests combined with our manufacturing experience and scale, we can provide the means to accelerate access to rapid testing. This means faster diagnosis and screening in the field, accelerating the ability of decision makers to deploy a more rapid response to results. We are committed and honest in all that we do. We value the quality and contribution of all, priding ourselves on building long-lasting and trusting partnerships – because by working transparently with customers, partners and colleagues, we are better together. With an exceptional pedigree in developing and manufacturing rapid tests Abingdon Health are expert in responding to our customers varied needs with specific and customisable solutions. Our mission: To improve life by making rapid results accessible to all. By providing the best lateral flow rapid test solutions, we believe we can support the increase in access to diagnostics across many industries and locations throughout the world. Faster access to results allows for rapid decision making and solutions. This ability has a significant role to play in improving life in so many ways.

Aelius Biotech is a UK-based biotechnology company founded in 2018, located in Newcastle upon Tyne. The company specializes in developing in vitro gastrointestinal models, which simulate the digestive process. This innovative model includes cell-compatible mucus, allowing for a comprehensive understanding of digestion and absorption. Aelius Biotech offers contract research services focused on animal-free testing for pharmaceuticals, consumer health products, and functional foods. They have collaborated with notable clients, including Huel, and have attracted interest from the alternative protein and lab-grown meat sectors. The company has experienced significant growth, expanding its workforce and revenue following successful funding rounds in 2023 and 2025.

Who are we? We are AF ChemPharm, established in Sheffield, England, in 1998. We are a chemistry-based contract research organisation, and are specialists in driving discovery by simplifying synthesis. We provide a straightforward, cost-effective and convenient route for bringing expertise in chemical synthesis into your projects. Whatever your core focus, AF ChemPharm is on hand to help you streamline your workflow if you require chemical synthesis. Though we are principally involved in the drug discovery and pharmaceutical sectors, we are a reactive and versatile company, and have current and previous clients from a diverse range of industries. We've worked with biomedical academic research groups, functionalised polymer manufacturers, fine chemical suppliers and emerging-technology firms, amongst many others. What do we offer? Our clients expect high quality, reliable and cost-effective consultancy, custom synthesis and contract research, and we are proud to say that we can deliver on these expectations. We are situated in purpose-designed, state-of-the-art laboratories in central Sheffield, equipped with kilo-lab facilities, and we use a world-class analytical suite for the characterisation of your projects. We work with multi-national companies, universities, SME's and brand new start-ups; whatever the size and direction of your company, we pledge the same commitment to excellence in science, communication and customer service . Our team are all PhD chemists, with backgrounds in synthetic organic and organometallic chemistry from both academia and industry, and we have recently appointed two external scientific advisors of the highest calibre - Prof. Joe Harrity of Sheffield University and Prof. Alan Spivey of Imperial College, London.

Antiverse is a Welsh techbio company specialising in antibody design for challenging drug targets, such as GPCRs and ion channels. We exist to create new enabling technologies that bring new therapies to patients to change lives. Headquartered in Cardiff, UK and with offices in Boston, MA, we combine state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics.

APIS is leveraging systems biology, interrogating multi-OMICs biodata, and deploying innovative ‘Clickmer’ ligand binding technology, for the validation and translation of biomarker and therapeutic assets into clinical utility. APIS has deep expertise and capabilities in IVD development of molecular & immune assays for ultimate product realisation as diagnostic tests. In addition, APIS' expertise in bioinformatics and software development is offered as an agile service to our clients, to develop bespoke, end-to-end multi-OMICs solutions and platform development. APIS has also developed a broad breast oncology product portfolio: The APIS Breast Cancer Subtyping Kit is a reproducible RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers. The APIS ESR1 Mutations Kit is a qPCR assay for the sensitive detection of eleven key mutations within the oestrogen receptor gene. Coming soon - the new APIS PIK3CA Mutations Kit is a qPCR assay for the sensitive detection of key mutations in the PIK3CA gene.

Arctoris Ltd is a biotechnology company founded in 2016 and based in Oxford, UK, with additional locations in Singapore, Boston, and Abu Dhabi. It operates as a tech-enabled Partnership Research Organization (PRO) and utilizes its proprietary Ulysses platform, the first fully automated drug discovery platform, to enhance research and development processes for biotech, pharmaceutical, and academic partners. The company employs over 40 experts in various fields, including cellular and molecular biology, biochemistry, and machine learning. Arctoris offers services such as Experiments-as-a-Service, integrated drug discovery, and collaborative R&D, providing end-to-end support from target identification to preclinical candidate development. The Ulysses platform combines robotics and advanced data science to deliver high-quality datasets, reducing human error and accelerating project timelines. Arctoris collaborates with biotech startups, large pharmaceutical companies, and AI-driven drug discovery firms, focusing on oncology, neurology, and other therapeutic areas.

Astoriom is a globally recognised leader in outsourced stability storage and biorepository solutions, with over 30 years of industry experience. We specialise in providing comprehensive stability storage and validation services to pharmaceutical companies, biotech firms, medical device manufacturers, and other life science organisations worldwide. Our services ensure the highest standards of quality and compliance, making us a trusted partner in the industry. Why Astoriom: - Expert Team: Our highly experienced and trusted professionals ensure the highest quality of service. With decades of expertise, our team is dedicated to maintaining the integrity of your products. - Extensive Capacity: We offer over half a million cubic feet of storage at all ICH conditions, accommodating a wide range of temperatures from liquid nitrogen-cooled -196C to +60C. This vast capacity allows us to meet diverse client needs efficiently. - State-of-the-Art Systems: Our automated inventory system and 24/7 alarming ensure robust security, and continuous monitoring. Our systems are designed to provide real-time updates and immediate alerts to ensure the safety and stability of your products. - On-Site Engineers: Dedicated service and validation engineers are available on-site, providing immediate support and maintenance ensuring the continuous operation of storage systems. Astoriom's Core Services: - Stability Storage - Biorepository - Accelerated Ageing Testing - Disaster Recovery - Photostability - Thermal Cycling - Validation Service - 24/7/365 On-Call Repair At Astoriom, every sample matters because everyone's health matters. We are committed to treating each sample entrusted to us with the utmost care, providing reliable and innovative solutions worldwide to ensure the integrity and safety of your products.

BBI Solutions - Serving the Science of Diagnostics BBI Solutions is a leading expert in immunoassay development and manufacturing services, and provides an extensive portfolio of products and technologies to the global research and diagnostic markets. The contribution that the BBI Group makes towards achieving this is by adhering to our Mission; ‘To deliver exceptional products and technologies that people rely on to enjoy a better quality of life. Through innovation, partnership, effective delivery and the collaboration of our people, we constantly strive to help set industry standards, engender trust and build our reputation for excellence

Cambridge Nucleomics is a biotechnology company that specializes in fast and easy RNA measurement at scale with single-molecule accuracy.

Celentyx Ltd is a ‘boutique’ CRO providing bespoke drug discovery services focused on human immunology across a broad range of therapeutic areas including autoimmunity, COVID-19, inflammation, immuno-oncology, fibrosis and neuroinflammation. Celentyx has a highly experienced scientific team that develops and provides assays using human primary cells at all stages of the drug discovery pipeline. Situated in close proximity to major hospitals and blood services (with established partnerships), assays can be performed at scale using blood and tissue from healthy volunteers and patients with defined disease including deep access to their clinical records. Celentyx has well-established assay platforms in multi-colour flow-cytometry, Cytof, high-content imaging, multiplex supernatant analysis (Luminex), super-resolution microscopy as well as proteomic and molecular biology capability, enabling high-resolution analysis of the human immune system for target discovery, screening, candidate selection, mechanism of action, and biomarker studies. Celentyx is based in the UK (Oxford and Birmingham) and in addition to internationally recognised scientists within the company, benefits from the world-leading expertise of neighbouring translational medicine departments at the Universities of Oxford and Birmingham.

Cellesce Ltd is a biotechnology company based in Cardiff, Wales, that focuses on organoid research and bioprocessing technologies. Established in 2013, the company specializes in patient-derived organoids (PDOs) for cancer research, utilizing patented bioprocessing technology to standardize and scale organoid production. The company offers several core services, including the development and manufacturing of standardized cancer organoids for large-scale applications such as compound screening and high-throughput drug discovery. Cellesce also provides scale-up solutions to ensure reproducible organoid batches, meeting the needs of pharmaceutical testing. Additionally, it supports drug discovery pipelines with customized organoid models, particularly in oncology. In December 2022, Cellesce was acquired by Molecular Devices, enhancing its capabilities in integrating organoid technology into drug discovery platforms. The company reported $7.8 million in annual revenue for 2024 and operates with a small team, emphasizing its commitment to advancing organoid-based precision medicine.

Pharmaceutical Services

CN Bio is a leading organ-on-a-chip (OOC) company that enables researchers to improve the accuracy and efficiency of preclinical drug discovery. Our PhysioMimix® suite of microphysiological systems, 3D-validated cells, consumable plates, and Contract Research Services facilitate the prediction of human responses to drug exposure, in the presence or absence of disease, so that new medicines can be brought to market more rapidly, cost-effectively and using fewer animals. Utilizing primary cells, our perfused single (Lung, Liver), and multi-organ (Intestine/Liver, Lung/Liver) models recapitulate the microarchitecture, microenvironment and function of their human counterparts in vitro. The approach provides a viable alternative to animal models where translatability to humans is predicted to be poor and for testing advanced drug modalities where human-specific targets and pathways are required. They generate physiologically relevant, human-translatable, mechanistic data that enables researchers to progress only the safest and most efficacious drugs into in vivo animal studies and be better prepared for clinical trials. Please follow us for regular updates. It starts here.

For over 30 years, FUJIFILM Diosynth Biotechnology’s mission has been advancing tomorrow’s medicine. As a CDMO, we work in partnership with the most innovative biopharma and biotech companies across the world who are reimagining healthcare’s potential. We help to accelerate their progress, expand their capabilities, streamline their processes, and strengthen their innovation. So when our customers’ potential cures, vaccines, biologics, and accomplishments make strides – or even become new realities for patients – we know our work, our manufacturing expertise, and our partnership helped make it happen. FDB isn’t simply a workplace. It’s a place of passion – a place of what we call Genki. A place where diverse perspectives and people come to life. Where opportunity for growth has no end. Where passion is followed, discovered, and nurtured. Where the energy is undeniable, enthusiasm is pervasive, and drive is infectious. All of our global locations burst with curiosity, inspiration, and extraordinary purpose. So as we continue to grow our teams, our global locations, and our capabilities, Genki will always be our cultural tie. That’s why we’re always looking for passionate, mission-driven people who want to commit their life’s work to enabling better outcomes for patients and their families. For a full listing of jobs that will propel, inspire, and fulfill you, please visit: fujifilmdiosynth.com/careers/ We created this space on LinkedIn to give people a window into work and culture at FDB. We’re highlighting employees’ passion, current openings, and why it’s never been a more exciting time to join FDB.

Since 2001, Fusion Antibodies has been dedicated to the discovery and early development of antibodies to help bring about a positive change in the healthcare industry. We offer a complete range of antibody-related services in Discovery, Engineering and Supply and have guided hundreds of projects through critical preclinical stages. Fifteen of our client's projects have advanced to clinical stages, some as far as Phase II. We deliver a superior service for the development of antibodies by beginning each project with the end in mind. Our scientists are experts in early stage discovery of biologics. We offer this personalised service because we know that investment at the early stages saves not only millions of dollars but also months, even years of time, on projects that go awry at later stages of development. Through our vast experience we have developed a number of our own proprietary platforms for Antibody Humanization (CRX™), Affinity Maturation (RAMP™) and Developability optimisation (ADD™). Fusion Antibodies is a publicly held company, trading on the London Stock Exchange (LSE FAB.L) with headquarters in Belfast, Northern Ireland.

Gentronix is a specialist CRO focused on delivering predictive toxicology products & services to global chemical sectors. Working with companies from early screening through to regulatory safety assessment, we deliver innovative solutions for both genetic toxicology and skin sensitisation. For 20 years, Gentronix Ltd has provided predictive toxicology solutions to global chemical industries; enabling our clients to optimise their development programmes via early identification of genotoxic hazard and assessment of chemical safety. Gentronix offers a comprehensive portfolio of screening and regulatory genotoxicity products & services, along with assessment of skin sensitisation potential.

hVIVO plc (ticker: HVO) is a fast growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies. The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Group has world class challenge agent manufacturing capabilities, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group also offers additional clinical field trial services such as patient recruitment and clinical trial site services. hVIVO runs challenge trials in London - its new state-of-the-art facilities in Canary Wharf opened in 2024 and is the world's largest commercial human challenge trial unit, with highly specialised on-site virology and immunology laboratories, and an outpatient unit. To recruit volunteers / patients for its studies, the Group leverages its unique clinical trial recruitment capability via its FluCamp volunteer screening facilities in London and Manchester.

Advancing medicine and human health by transforming data into clinically meaningful insights. IXICO is a premier neuroimaging provider helping biopharmaceutical companies maximize the value of their drug development pipelines by transforming data into clinically meaningful insights. Bringing together world-class therapeutic expertise, breakthrough analytics and operational excellence, IXICO is the proven partner of choice for imaging biomarker solutions in CNS clinical trials.

Leaf Expression Systems is a translational R&D and contract manufacturing business focused on the plant expression of proteins, vaccines, and complex natural products. They use the power of plant-based expression and plant biotechnology to enable their partners to innovate and impact, helping to drive their productivity and create.

An innovative C. elegans company, using our expertise and technology to provide quantified non-invasive assays of health outcomes for biotech, nutrition and other industries and research interests. - Prescreen compounds to reduce the number of experiments in mammals - Find effective and safe concentration ranges
 - Test mutants in signalling pathways - Screen libraries of mutants
 - Screen compound libraries 
 - Combine compounds and mutants
 - Adapt technology to address your questions We are a team of experts with a proven track record of: Designing customised C. elegans studies to provide answers to your specific ageing research questions Integrating C. elegans into drug discovery pipelines Working with innovative biotech and pharma companies Providing relevant, standardised, data rich assays

Malvern Panalytical is a global leader in the analytics of material and life sciences. We unleash the power of small things to make big things happen for our customers. Our vision is to make the world cleaner, healthier, and more productive. We partner with our customers to make their solutions possible through the power of precision measurements, our expertise, trusted data, and insights. Our people are partners in discovery. We collaborate with our customers and with each other to discover new possibilities and achieve breakthroughs. Our culture is a healthy, high-performance culture shaped by our values: Own it, Aim High and Be True. We’re committed to Net Zero in our own operations by 2030 and in our total value chain by 2040. With over 2300 employees across the globe, we are part of Spectris plc, the world-leading precision measurement group. Malvern Panalytical. We’re BIG on small™

Medherant is a clinical-stage company developing innovative treatments using its novel transdermal drug delivery technology, the TEPI Patch, which is based on a proprietary adhesive developed by its scientists. The Company was founded by Professor David Haddleton and the University of Warwick in 2015 based on their world-leading expertise in bioadhesives and polymer chemistry. The adhesive has a high drug loading capacity, so a smaller quantity of adhesive is needed to deliver a therapeutic dose; the patch can therefore be thinner and more flexible. It also enables excipients, such as permeation enhancers, to be included in the adhesive so the release of the drug from the patch can be tailored to achieve the desired product profile. The adhesive also provides excellent adhesion, even in moist conditions. This means that the patch remains in contact with the skin throughout the dosing period, so the full dose is delivered. There is no leakage of adhesive from the patch so there is no unsightly black ring around its edge and no residue on the skin after removal. Medherant undertakes feasibility studies for other companies to investigate whether their drugs can be formulated for transdermal delivery using the TEPI technology. Medherant welcomes enquires from companies interested in licensing its products for commercialisation or undertaking feasibility studies.

Metrion Biosciences is a specialist preclinical drug discovery CRO - your trusted partner for ion channel screening, cardiac safety screening and neuroscience assays. We provide our customers with a range of in vitro screening services, including cardiac safety (GLP hERG, CiPA panel of human cardiac ion channels) and neurotoxicology testing and phenotypic assays on a fee-for-service or collaboration basis. We pride ourselves on being able to provide a flexible and cost effective service with an unparalleled level of expertise. Collectively, we have 250 years experience managing ion channel research programmes.

Helping medical device Sponsors improve healthcare since 1967, NAMSA is the world's leading MedTech Contract Research Organization (CRO) offering global end-to-end development services. Driven by its global regulatory expertise and in-depth therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development, offering only the most proven solutions to move clients' products through the development lifecycle efficiently and cost-effectively. From medical device testing; regulatory, reimbursement and quality consulting; and clinical research services, NAMSA is the industry's premier, trusted partner for successful development and commercialization outcomes. Learn more: https://namsa.com/about/client-testimonials/

NunaBio is a privately-owned specialist DNA synthesis and development company. We are engaged in CRO (Contract Research Organizations) and CDMO (Contract Development and Manufacturing Organisation) activities. The company has built a solid reputation for its R&D flexibility and innovative approach to complex and challenging projects. NunaBio's core expertise is research and development into cell-free DNA synthesis, process optimisation, route design, scale-up and small-scale manufacture for clinical studies.

OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.

Perceptive Inc. is a global technology-enabled service provider dedicated to the biopharmaceutical industry. Recently rebranded as "Perceptive," the company focuses on advancing life-changing treatments through innovative services and solutions. Perceptive offers a range of services, including Perceptive Discovery, which aids in preclinical and first-in-human imaging to identify promising compounds. The Perceptive eClinical division enhances patient and clinical supply management, featuring services like Randomization & Trial Supply Management and Interactive Response Technology. Additionally, Perceptive Imaging provides expertise in scientific, regulatory, and operational aspects to support efficient data collection in clinical trials. With a client base that includes many leading pharmaceutical and biotech companies, Perceptive operates globally, ensuring smooth execution of clinical trials across various regions. The company has played a significant role in supporting nearly 12,000 clinical research trials and over 800 approvals, particularly in oncology and neuroscience, while upholding values of customer-centricity, quality, and accountability.

Services

Provide formulation development, clinical pharmacology trials, and clinical and commercial manufacturing services to the pharmaceutical and biotech industry.

Selcia, now part of Eurofins, is a global leader in 14C custom radiolabelling, stable isotope labelling and analytical services. With many years of experience our team of expert synthetic radiochemists can prepare radiolabelled molecules of almost any complexity for use in regulatory studies by the life sciences and chemical industries to understand: preclinical and clinical drug metabolism, human mass balance (GMP 14C Radiolabelled API), dermal penetration, tissue distribution and environmental fate. Selcia also offers GLP NMR and analytical problem solving services to support regulatory submissions, as well as the profiling and synthesis of metabolites and process impurities. 14C Custom Radiolabelling for pre-clinical ADME studies 14C Custom Radiolabelling for pre-clinical studies (ADME, Dermal Penetration, E-fate) GMP Radiolabelled API for Clinical Trials , 14C-API for hAME and mass balance Stable Labelling (13C, 2H, 15N) Internal Standards, Metabolites and Impurities Stable Labelling 13C 2H 15N GLP Analysis Certification and Problem Solving including GLP NMR www.selcia.com contact@selcia.com

great people, great work, real results Sequani's heritage spans more than 50 years when a company called Toxicol Laboratories opened for business in London. A little while later the company moved to the current site in Ledbury's Bromyard Road. Toxicol Laboratories then joined with Quintiles and the foundations were laid for the company as it is today. The name Sequani dates back to the year 2000 when, after seven years of association with Quintiles, the company changed ownership under a new identity. The name Sequani comes from a Celtic tribe made famous for harrying invading Romans during their suppression of Gaul. We feel the name is apt as we too give the big boys a run for their money! We achieve this by working closely with you to deliver flexible and fast solutions that help keep your development programmes on schedule. Our customer feedback consistently shows that the service and commitment our clients enjoy is the most personal and direct in the business. But we take none of this for granted. Our focus is continuous improvement so that we carry on growing through the repeat business of loyal customers as well as attracting business from new clients.

Sygnature Discovery is a world-leading integrated drug discovery Contract Research Organisation, with over 1000 staff from 53 nationalities, including 900 scientists working on drug discovery programmes. Founded in 2004, we have delivered over 40 pre-clinical compounds, 21 clinical compounds, and our scientists are named on over 170 patent applications. We partner with global pharma, biotech, and NFP organizations, providing integrated drug discovery services from target identification through to candidate nomination. Our co-located teams are experts in protein science, chemistry, computational chemistry, in vitro biology, pharmacology, DMPK, form and formulation services, and project management, with a core therapeutic focus on oncology, inflammation and immunology, as well as neuroscience, metabolic diseases, respiratory, infectious diseases and fibrotic diseases.

SyntheticGestalt is an AI startup focused on the life sciences sector, particularly in drug and enzyme discovery. Founded in 2018, the company operates from dual headquarters in London and Tokyo. It utilizes advanced machine learning models to enhance the design, discovery, and analysis of both small and large molecules. The company offers services in drug and enzyme discovery, collaborating with prestigious universities in the UK and Japan. This partnership emphasizes its commitment to scientific research and development in biotechnology. SyntheticGestalt has a diverse international team with expertise in entrepreneurship, pharmaceuticals, consulting, and AI, fostering a supportive work environment that encourages professional growth. With a small team of 11 to 50 employees, SyntheticGestalt is a private limited company incorporated in the UK. Its operations reflect a strong dedication to innovation in the life sciences, supported by grants and collaborations with academic institutions.

Tepnel Pharma Services is a Scottish based FDA and MHRA inspected contract research laboratory. We support pharmaceutical research and development for both small and large molecules with an emphasis on inhalation, oral dosage, parenteral and peptides/proteins. The mission of Tepnel is to Support Drug Development whilst Improving Patient Outcomes. A major aspect of this is helping to address the paradigm of sustainable healthcare economics within a post Brexit, 21st century healthcare system. Our aim as a Scottish owned company is to grow in Scotland, develop our business in Scotland and challenge the perceived ways of working to create a new but compliant way of working that adopts a vested philosophy whereby mutuality of benefit is delivered to our stakeholders around our quality framework that ensures total quality from start to finish.

Ubiquigent enables the discovery and development of novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need. Founded 13 years ago, the Company has an unrivalled track record and unique range of specialist services focused on the exploitation of the DUB enzymes and ubiquitin-proteasome system (UPS). As the partner chosen by many leading industry and academic organisations for their drug discovery programmes, Ubiquigent's experience spans the development of DUB inhibitors and modulators in the fields of protein degradation, stabilisation, and homeostasis. Ubiquigent has an internal pipeline of drug discovery programmes and is developing a strong IP portfolio encompassing DUB inhibitors, DUB-targeting Proteolysis Targeting Chimeras (PROTACs) and DUB-Targeting Chimeras (DUBTACs) for partnering and commercialisation.